CD274 and neoplasm: Currently approved immunotherapies target immune-inhibitory receptors (e.g. PD-1 and CTLA-4) on T lymphocytes, or their ligands (e.g. PD-L1), aiming to activate T-lymphocyte cytotoxicity and anti-tumour immunity [5].